University of Ioannina
Ο ρόλος των κανναβινοειδών σε πειραματικά πρότυπα ψύχωσης: εστιάζοντας στην κανναβιδιόλη
Abstract
dc:descriptionSchizophrenia is a debilitating mental disorder with a high lifetime prevalence that cannot be adequately addressed by current pharmacological approaches. The development of novel therapeutic approaches is constantly challenged by the elusive understanding of the pathophysiological mechanisms and the lack of preclinical models that display construct and predictive validity. Clinical studies provide promishing data regarding the antipsychotic potential of cannabidiol (CBD), the major non-addictive component of Cannabis sativa. However, preclinical studies display considerable inconsistencies in this regard, while there is a lack of prominent mechanistic explanations for CBD’s antipsychotic action.The objective of this dissertation lays on the evaluation of CBD’s antipsychotic action using preclinical models that mimic the dysfunction in the dopaminergic and the glutamatergic system by administrating d-amphetamine and ketamine respectively, to rats.CBD did not counteract the hyperlocomotion and sensorimotor deficits that acute d-amphetamine elicited, which resemble psychotic symptomatology. However, following amphetamine sensitization which is considered a schizophrenia-related bio-phenotype reflecting aspects of positive symptomatology, CBD was able to mitigate the exaggerated response to acute d-amphetamine, ameliorate the sensorimotor gating dysfunction, while modulating the underlying deviations of dopaminergic function in the ventral striatum.Acute subanesthetic ketamine treatment, used to mimic NMDA receptor dysfunction in schizophrenia, induced transient hyperlocomotion. CBD prolonged this effect to a broader time frame and also resulted in a sustained increase in dopaminergic neurotransmission in the nucleus accumbens.Repeated ketamine administration has been used as a preclinical model that resembles positive, negative, and cognitive symptomatology in schizophrenia. Additional to this behavioral phenotype, we have observed a dampened dopaminergic neurotransmission in the prefrontal cortex (PFC) and elevated biosynthesis rate in the dorsomedial striatum (DMS). Glutamatergic status was also altered, with increased glutamate cycling rate in the PFC and decreased rate in the DMS. This opposite fashion of alterations was also profound in the of excitation:inhibition (E:I) imbalance, which was observed as power spectrum densities. However, the coherence between PFC and the ventral hippocampus, as well as the PFC and DMS did not display major effects of ketamine. The E:I imbalance could be attributed to the reduced density of parvalbumin-immunoreactive interneurons observed, or the increase of cannabinoid receptor in the perisomatic terminals of cholecystokinin expressing interneurons, since these two interneuron subtypes play a central role on tuning brain rhythmic activity.CBD attenuated positive, negative, cognitive symptomatology examined, reversed the deviations of dopaminergic and glutamatergic neurotransmission, and restored the E:I balance in the PFC, while displayed subtle mitigatory action for the corresponding ketamine-induced effects on the DMS. Additionally, CBD attenuated ketamine effects on parvalbumin- and cholecystokinin-immunoreactive interneurons, suggesting that its behavioral antipsychotic effects are connected to a multi-level action in the underlying neurobiological mechanisms, stretching from the local micro-circuit function and the regulation of E:I balance to the glutamatergic and dopaminergic neurotransmission, presenting more robust effects on the PFC rather than the striatum.Overall, our data support that CBD is not displaying a robust antipsychotic action on psychosis-related pathological manifestations induced by acute administration of psychotomimetic drugs. However, it exhibits a broad range of modulatory actions on the neurobiological underpinnings of positive, negative, and cognitive symptomatology, when studied using established bio-phenotypes that resemble schizophrenia-related pathologies.
Degree
thesis:*- Grantor dc:publisher
- University of Ioannina
- Year dc:date
- 2022
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Brakatselos, Charalampos
- Μπρακατσέλος, Χαράλαμπος
Subjects
dc:subject × 50- Κανναβιδιόλη
- Κεταμίνη
- Επίμυες
- Σχιζοφρένεια
- Ντοπαμίνη
- Γλουταμικό
- Φασματική πυκνότητα ισχύος
- GABAεργικοί ενδονευρώνες
- In vivo ηλεκτροφυσιολογία
- Προσδιορισμός βιογενών αμινών με HPLC-ED
- Ανάλυση αποτυπώματος κατά Western
- Ανοσοϊστοχημεία
- Γνωστικές διεργασίες
- NMDA υποδοχείς
- Προκλινική έρευνα
- Μοντέλα συμπεριφοράς
- Αμφεταμίνη
- Ανισορροπία διέγερσης/αναστολής
- Ραβδωτό σώμα
- Προμετωπιαίος φλοιός
- Cannabidiol
- Ketamine
- Rats
- Schizophrenia
- Psychosis
- HPLC-ED biogenic amine determination
- Western blot
- Immunohistology
- Novel object recognition test
- Open field
- Locomotor activity
- D-amphetamine
- Behavioral analysis
- In vivo electrophysiology
- Local field potentials
- GABAergic interneurons
- Preclinical research
- Dopamine
- Glutamate
- Excitation/inhibition imbalance
- Striatum
- Prefrontal cortex
- Βασική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Νευροεπιστήμες
- Φαρμακολογία και Φαρμακευτική
- Basic Medicine
- Medical and Health Sciences
- Neurosciences
- Pharmacology and Pharmacy
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/53959